-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...

The crux of the problem is not leakages, but unsold stocks. The debate on the public distribution system is being increasingly overwhelmed by the issue of corruption. The pressures on the system are seen primarily, if not entirely, as one of leakages. This preoccupation with leakages has reached a point where the government appears set to throw up its hands and just hand over cash to families, irrespective of whether they...

The chattering classes of urban India are engaged in animated discussions about Didi, scams, policy paralysis , faltering reforms and declining growth. Meanwhile, the farming classes, who haven't seen much reform since the Green Revolution 50 years ago, continue to combine bits of modern technology with their ingenious capacity for 'jugaad' in transforming traditional agriculture. Here are a few examples. The tractor displaced the bullock in ploughing and other farm operations....

Alarmed by its proactive role, the three ‘pillars’ of our democracy set out to weaken the fourth estate Fundamentalisms do not necessarily announce their arrival by banging a hammer on our heads. Freedoms are often lost in little steps. The process creeps in quietly but insidiously. The path is often complex and defies a simple narrative. But here’s a straightforward fact: a concerted attempt is being made to censor, control...

Fighting cancer has just become less expensive for millions of Indian patients. More than 12 years after he electrified the pharma industry by taking on powerful global giants in his quest to supply cheap anti-AIDS drugs, Cipla promoter YK Hamied is back donning the role of a price warrior. This time, his attention is on anti-cancer drugs. On Thursday, Cipla cut prices of key cancer drugs by nearly 75%, an astounding,...